Precipio, Inc. is a healthcare biotechnology company focused on improving cancer diagnostics, particularly for hematologic malignancies. The company operates through two complementary divisions: a Pathology Services Division that provides specialized diagnostic testing services, including molecular diagnostics and cytogenetics, to physicians, hospitals, and laboratories; and a Products Division that develops and commercializes proprietary diagnostic assays and kits for use by other clinical laboratories. Precipio serves the United States domestic oncology market, leveraging its clinical laboratory operations to generate data and validate products for its proprietary technologies. Its product portfolio includes molecular kits for detecting driver mutations in blood cancers such as MPN, CML, CLL, AML, and MDS, as well as multi-cell lineage culturing media. The company utilizes an integrated operating model where clinical services support research and development, enabling rapid assay development and validation using patient specimens and operational experience.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Diagnostics & Research Homepage precipiodx.com
Sector Healthcare IR page precipiodx.com/investors
Tags
hematologic malignancies, molecular diagnostics, cytogenetics, blood cancer, diagnostic assays, clinical laboratory services, oncology diagnostics, mpn, cml, cll, aml, mds, Bloodhound BCR-ABL1, Bloodhound ABL1 Resistance, Bloodhound MPN, HemeScreen AML, HemeScreen Cytopenia, HemeScreen CLL, IV-Cell Cytogenetics Culture Medium
Press page precipiodx.com/investors/press-releases

Metrics

Valuation  
Market cap $ 42.457M
Market cap (USD) $ 42.457M
P/E -37.11
PEG —
P/BV 2.86
P/S 1.51
P/OCF 24.97
P/FCF 30.61
Dividend yield —
Turnover / mcap —
Returns  
ROE -2.7%
ROI -2.5%
ROIC -6.2%
Profit margin -1.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 2.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 16
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 24.246M 18.576M 15.415M 9.82M 8.697M 7.431M 4.095M 3.448M 1.723M 1.557M 1.653M 27.083M 27.544M 31.48M 31.971M 20.048M 22.023M 23.993M 23.176M 23.415M 25.828M 33.789M 33.866M 37.554M 38.467M 25.883M
Net profit -363K -4.29M -5.853M -12.178M -8.517M -10.598M -13.243M -15.694M -20.694M -7.616M -32.954M -13.942M -15.987M -8.327M -9.782M -3.134M -1.92M -495K -2.107M -3.431M -14.993M -34.372M -22.958M -21.365M -7.401M -8.661M
Free cash flow 359K 216K -3.685M -7.998M -7.259M -7.585M -9.196M -6.851M -6.833M -3.569M -12.582M -13.832M -9.078M -11.086M -11K -1.91M 916K -738K -3.659M -1.462M -4.268M -10.859M -19.658M -29.412M -16.823M -7.857M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 22.98 5.54 6.5 0.55 1.58 2.07 2.04 0.15 1.2 — — — — — — — — — — — — — — — — —
Price performance 12m 3.15 -0.15 10.79 -0.65 -0.24 0.01 12.71 -0.88 — — — — — — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 225,000 730,000 690,000 574,000 874,000 697,000 1.04M 1.3M 799,000 1.98M
↳ YoY growth -14.8% +224.4% -5.5% -16.8% +52.3% -20.3% +48.6% +25.6% -38.6% +148.3%
↳ 5y CAGR -50.5% -38.2% -33.5% -40.4% +27.1% +25.4% +7.3% +13.5% +6.8% +17.8%
Borrowings, current (USD) 7.81M 587,000 263,000 321,000 648,000 26,000 255,000 235,000 297,000 30,000
Borrowings, non-current (USD) 0.00 2.83M 253,000 198,000 362,000 160,000 134,000 106,000 77,000 47,000
Lease liabilities (USD) — — 212,000 697,000 481,000 1.24M 1M 775,000 879,000 3.58M
Cash and deposits (USD) 110,000 421,000 381,000 848,000 2.66M 11.7M 3.45M 1.5M 1.39M 2.65M
Intangible assets (USD) 562,000 20.5M 19.3M 16.7M 15.7M 14.7M 13.8M 12.8M 11.9M 10.9M
Right-of-use assets (USD) — — 750,000 519,000 335,000 858,000 763,000 612,000 395,000 2.57M
Net debt (borrowings + leases - cash) (USD) 7.7M 3M 135,000 368,000 -1.17M -10.2M -2.05M -386,000 -136,000 1M
Cash flow detail
Operating cash flow (USD) -3.55M -6.69M -6.75M -9.14M -7.43M -6.58M -7.72M -3.56M 439,000 685,000
Purchases of property, plant and equipment (USD) -19,000 -143,000 -97,000 -55,000 -151,000 -682,000 -277,000 -126,000 -223,000 -326,000
Change in receivables (cash effect) (USD) -33,000 -495,000 -541,000 -850,000 -1.64M 327,000 -745,000 -483,000 438,000 -1.36M
Change in inventories (cash effect) (USD) 26,000 -46,000 -36,000 13,000 -166,000 -214,000 -144,000 324,000 -340,000 -211,000
Change in payables (cash effect) (USD) 3.09M 500,000 309,000 -1.88M -243,000 112,000 165,000 -169,000 -10,000 513,000
Interest paid (cash effect) (USD) 0.00 -107,000 -42,000 -36,000 -20,000 -34,000 -45,000 -42,000 -85,000 -100,000
Share-based compensation (USD) 52,000 49,000 529,000 668,000 703,000 1.88M 3.8M 1.56M 1.49M 1.21M
Operating cash flow before change in receivables (USD) -3.52M -6.2M -6.21M -8.29M -5.8M -6.9M -6.98M -3.08M 1,000 2.05M
Free cash flow (OCF - PPE - intangibles) (USD) -3.57M -6.83M -6.85M -9.2M -7.59M -7.26M -8M -3.69M 216,000 359,000
Income detail
Research and development expense (USD) 1.42M 500,000 1.1M 1.2M 1.2M 1.3M 1.7M 1.7M 1.3M 1.6M
↳ 5y CAGR -8.5% -27.5% -19.3% -16.2% -8.3% -1.8% +27.7% +9.1% +1.6% +5.9%
Total comprehensive income (USD) -7.62M — — — — — — — — —
Comprehensive income to owners (USD) -7.62M — — — — — — — — —
Provision for credit losses (USD) 72,000 310,000 581,000 966,000 1.34M -150,000 406,000 218,000 64,000 177,000
Credit cost ratio (credit losses / average receivables) (%) 29.4% 64.9% 81.8% 152.8% 184.9% 19.1% 46.9% 18.7% 6.1% 12.7%
Reported Apr 13, 2017 Apr 13, 2018 May 16, 2019 Mar 27, 2020 Mar 29, 2021 Mar 30, 2022 Mar 30, 2023 Mar 29, 2024 Mar 27, 2025 Mar 30, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Precipio Announces Q3-2026 Financial Results Bull 3 Bear 0 Results

Record quarterly revenue, positive Adjusted EBITDA, and strong operating cash flow - all position Precipio for accelerated future growth

NEW HAVEN, CT, Globenewswire – (Nov 10, 2026) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces third-quarter financial results for the quarter ending September 30, 2026.

Below are some of the key financial performance metrics for the Company. For additional results, please see the Company’s Form 10-Q filed today.

● Revenue – $7.3M, up 8% year-over-year from $6.8M in Q3-2025 and from $7.0M in Q2-2026. This comprises $1.0M in product revenue (up 40% year-over-year from $0.7M in Q3-2025, and $0.9M in Q2-2026), and $6.3M in pathology revenue (up 5% year-over-year from $6.0M in Q3-2025, and $6.1M in Q2-2026).

● Adjusted EBITDA – $0.4M vs. $0.5M in Q3-2025 and $0.4M in Q2-2026.

● Cash flow - Cash flow from operations was $0.6M in Q3-2026; total cash increased by $0.5M, resulting in an end-of-quarter cash balance exceeding $3.5M, vs $2.3M in Q3-2025.

Precipio, Inc. — Regulation FD Disclosure Bull 0 Bear 0 Routine

On October 28, 2026, Precipio, Inc (the "Company") announced that management will host a Q3-2026 Shareholder Update Call on November 10th, 2026, at 5:00 PM ET. The call will include updates on all of the Company’s current core businesses. This shareholders' update will incorporate a dedicated moderated live Q&A session into its quarterly update call. A copy of the letter is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Precipio Announces Q3-2026 Shareholder Update Call Bull 0 Bear 0 Routine

Posted on October 28, 2026 by Mehmed Iljazi

Conference Call will be held on November 10th, 2026, at 5:00 PM EST 

NEW HAVEN, CT, (October 28th, 2026) – Specialty cancer diagnostics company Precipio, Inc.  (NASDAQ: PRPO) , will be hosting its Q3-2026 shareholder update call on November 10th, 2026, at 5:00 PM ET. The call will include remarks on the Company’s current core businesses, as well as a moderated live Q&A session at the end of the Company remarks.

“This quarter, our continued revenue growth was strengthened by Products Division revenues exceeding an important milestone, which we will share in our upcoming shareholder call. As this is also the last shareholder call for the year, we will be sharing some thoughts about where we envision 2027 and beyond taking us”, said Ilan Danieli, CEO.

This call will incorporate a dedicated moderated live Q&A session into its quarterly update call. Following Ilan Danieli’s remarks, the conference call moderator will invite listeners to log into the Q&A system, where they will need to identify themselves and the organization they represent (or individual investor). Participants who wish to ask a question during the live call should follow the operator’s instructions.

Listeners interested in submitting questions in advance can email their questions to [email protected] , Management looks forward to addressing investor questions and providing additional insight into the Company’s performance, strategy, and growth initiatives.

The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call.

A replay of the call will be available approximately 24 hours after the call and may be accessed via the Investors page on Precipio’s website, https://www.precipiodx.com/investors/ .

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.

Availability of Other Information About Precipio

Prompts

Precipio, Inc. (ticker PRPO), listed in United States.

Company History

Date Change Detail
Jun 30, 2017 Renamed TRANSGENOMIC INC → PRECIPIO, INC.

ETFs Holding Precipio, Inc.

ETF Weight in ETF Shares Market value As of
DFSU 0.00% 1,008 $ 23.436K Nov 12, 2026
DXUV 0.00% 456 $ 10.602K Nov 12, 2026
DFAS 0.00% 1,781 $ 41.408K Nov 12, 2026
DCOR 0.00% 728 $ 16.926K Nov 12, 2026
DFAC 0.00% 579 $ 13.462K Nov 12, 2026